Farons upcoming EOP2 & pivotal trials.12 Jun 2025 06:27
I suspect we will be proposing 2 near-term development pathways at the upcoming FDA EOP2 meeting which gives Faron maximum optionality.
One which largely encompasses the Front Runner designation in line with what the company previously communicated.
And another for a single-arm pivotal trial in the r/r population. There is precedent for this & it is apparently encouraged by the FDA to explore all possible further development scenarios.
Given Farons fairly limited cash resources, a pivotal single arm r/r phase 3 would be achievable, perhaps encompassing the further €20m bond facility and / or potentially one further capital raise.
To my mind this strengthens Farons position to have the ability to ‘go it alone’ and get their first all-important approvals and to become a cash generating & profitable, self-sustaining biotech company.
If this does play out, I suspect the benefits of project Front Runner, to a deep pocketed pharma major, knowing Faron can solely take this to a self-funding business, raises the potential for significant deal making at an optimal valuation, be it partnering, license deals or full takeover, given Farons optionality & lack of needing a deal to continue the development of Bex.
I will be highly surprised if this is not what Faron are thinking / considering / proposing to the FDA.
Faron presenting at EHA this coming Sunday, offering more visibility & showcasing the outstanding data we are generating in this disease setting.
I suspect we are crystal clear on our forward path in the upcoming months, at latest by 2026, which marks a major inflection point as Faron moves closer toward first approvals, deal making and / or an outright takeover.
Good luck all, we are in the sweet spot here with limited near-term downside risk and a strong likelihood of company transforming developments.
All in my opinion, and always do your own research…
Sign In
Follow the stocks
